Product Details
Synonyms
FOLR2, BETA-HFR, FBP, PL-1, FR-BETA, FR-P3, FBP
Source
Cynomolgus FOLR2, His Tag (FO2-C52H8) is expressed from human 293 cells (HEK293). It contains AA Thr 34 - His 245 (Accession # A0A2K5U027-1).
Predicted N-terminus: Thr 34
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.5 kDa. The protein migrates as 33-43 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Cynomolgus FOLR2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-SPR

Immobilized Folic acid-BSA on CM5 Chip can bind Cynomolgus FOLR2 Protein, His Tag (Cat. No. FO2-C52H8) with an affinity constant of 1.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Folate receptor beta
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
2 Details
- Highest Development Stage:
Phase 3 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















